HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC
Clinical trial NCT05532319 · COMPLETED
Trial details
- NCT number
- NCT05532319
- Sponsor
- Guangxi Medical University
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-10
- Primary completion
- 2025-12-23
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.